Insider Buying: Zura Bio (NASDAQ:ZURA) Major Shareholder Acquires $12,500,000.00 in Stock

Zura Bio Limited (NASDAQ:ZURA) major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of the firm’s stock in a transaction dated Thursday, February 26th. The shares were bought at an average price of $6.25 per share, with a total value of $12,500,000.00. Following the purchase, the insider owned 6,552,725 shares in the company, valued at $40,954,531.25. This represents a 43.93% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Zura Bio Stock Performance

Shares of ZURA stock opened at $6.99 on Thursday. The stock’s 50 day simple moving average is $5.83 and its 200 day simple moving average is $4.17. Zura Bio Limited has a twelve month low of $0.97 and a twelve month high of $7.19. The company has a market capitalization of $454.49 million, a price-to-earnings ratio of -10.75 and a beta of 0.18.

Institutional Trading of Zura Bio

Several hedge funds and other institutional investors have recently bought and sold shares of ZURA. Allworth Financial LP bought a new position in shares of Zura Bio during the 4th quarter worth about $30,000. Squarepoint Ops LLC grew its position in Zura Bio by 34.6% during the fourth quarter. Squarepoint Ops LLC now owns 33,801 shares of the company’s stock worth $177,000 after buying an additional 8,680 shares in the last quarter. Bank of America Corp DE increased its stake in Zura Bio by 31.9% during the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after acquiring an additional 9,966 shares during the period. Scientech Research LLC acquired a new position in Zura Bio in the 3rd quarter valued at approximately $45,000. Finally, State Street Corp lifted its position in shares of Zura Bio by 8.3% in the 4th quarter. State Street Corp now owns 156,363 shares of the company’s stock worth $819,000 after acquiring an additional 12,000 shares during the period. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZURA has been the subject of several recent analyst reports. Wedbush started coverage on shares of Zura Bio in a report on Monday, February 9th. They set an “outperform” rating and a $15.00 price objective for the company. Chardan Capital reissued a “buy” rating and set a $10.00 target price on shares of Zura Bio in a research report on Friday, November 14th. Wall Street Zen cut shares of Zura Bio from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Leerink Partners raised Zura Bio to a “strong-buy” rating in a research report on Sunday, November 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $11.60.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.